Makiko Shimizu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3596707/publications.pdf

Version: 2024-02-01

186254 243610 2,936 161 28 44 citations h-index g-index papers 165 165 165 2929 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genomic Landscape of Esophageal Squamous Cell Carcinoma inÂa Japanese Population. Gastroenterology, 2016, 150, 1171-1182.	1.3	265
2	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochemical Pharmacology, 2007, 73, 2020-2026.	4.4	119
3	The <i>CYP3A4</i> intron 6 C>T polymorphism (<i>CYP3A4*22</i>) is associated with reduced CYP3A4 protein level and function in human liver microsomes. Journal of Toxicological Sciences, 2013, 38, 349-354.	1.5	70
4	Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients. Journal of Cardiovascular Pharmacology, 2015, 65, 289-295.	1.9	65
5	Transient trimethylaminuria related to menstruation. BMC Medical Genetics, 2007, 8, 2.	2.1	62
6	Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochemical Pharmacology, 2013, 85, 1588-1593.	4.4	61
7	Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity. World Journal of Gastroenterology, 2006, 12, 1071.	3.3	59
8	Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on N- and S-Oxygenation Activities. Drug Metabolism and Disposition, 2007, 35, 328-330.	3.3	55
9	Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. British Journal of Clinical Pharmacology, 2010, 69, 593-597.	2.4	52
10	Human Liver Microsomal Cytochrome P450 3A Enzymes Involved in Thalidomide 5-Hydroxylation and Formation of a Glutathione Conjugate. Chemical Research in Toxicology, 2010, 23, 1018-1024.	3.3	46
11	Human Blood Concentrations of Cotinine, a Biomonitoring Marker for Tobacco Smoke, Extrapolated from Nicotine Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling. International Journal of Environmental Research and Public Health, 2010, 7, 3406-3421.	2.6	45
12	Drug Interactions of Thalidomide with Midazolam and Cyclosporine A: Heterotropic Cooperativity of Human Cytochrome P450 3A5. Drug Metabolism and Disposition, 2009, 37, 18-23.	3.3	43
13	<i>In Vivo</i> Formation of Dihydroxylated and Glutathione Conjugate Metabolites Derived from Thalidomide and 5-Hydroxythalidomide in Humanized TK-NOG Mice. Chemical Research in Toxicology, 2012, 25, 274-276.	3.3	43
14	Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Molecular Genetics and Metabolism, 2007, 90, 58-63.	1.1	41
15	Cytochrome P450-depedent Drug Oxidation Activity of Liver Microsomes from Microminipigs, A Possible New Animal Model for Humans in Non-clinical Studies. Drug Metabolism and Pharmacokinetics, 2009, 24, 404-408.	2.2	41
16	Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochemical Pharmacology, 2014, 90, 159-165.	4.4	41
17	Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, <i>S</i> -Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. Drug Metabolism and Disposition, 2015, 43, 1408-1416.	3.3	41
18	Genetic Polymorphism of the Flavin-Containing Monooxygenase 3 (FMO3) Associated with Trimethylaminuria (Fish Odor Syndrome): Observations from Japanese Patients. Current Drug Metabolism, 2007, 8, 487-491.	1.2	36

#	Article	IF	Citations
19	Determination and prediction of permeability across intestinal epithelial cell monolayer of a diverse range of industrial chemicals/drugs for estimation of oral absorption as a putative marker of hepatotoxicity. Toxicology Reports, 2020, 7, 149-154.	3.3	36
20	Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans. Drug Metabolism and Pharmacokinetics, 2015, 30, 64-69.	2,2	35
21	Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology. Chemical Research in Toxicology, 2016, 29, 1903-1911.	3.3	35
22	Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenetics and Genomics, 2007, 17, 827-839.	1.5	33
23	Individual Differences in Pharmacokinetics and Pharmacodynamics of Anesthetic Agent Propofol with Regard to CYP2B6 and UGT1A9 Genotype and Patient Age. Drug Metabolism and Pharmacokinetics, 2011, 26, 532-537.	2.2	33
24	Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. Journal of Toxicological Sciences, 2012, 37, 1157-1164.	1.5	33
25	<i>In Vivo</i> Formation of a Glutathione Conjugate Derived from Thalidomide in Humanized uPA-NOG Mice. Chemical Research in Toxicology, 2011, 24, 287-289.	3.3	32
26	Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica, 2016, 46, 1049-1055.	1.1	31
27	Qualitative De Novo Analysis of Full Length cDNA and Quantitative Analysis of Gene Expression for Common Marmoset (Callithrix jacchus) Transcriptomes Using Parallel Long-Read Technology and Short-Read Sequencing. PLoS ONE, 2014, 9, e100936.	2.5	29
28	Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. European Journal of Clinical Pharmacology, 2010, 66, 1065-1068.	1.9	28
29	Biomonitoring of Urinary Cotinine Concentrations Associated with Plasma Levels of Nicotine Metabolites after Daily Cigarette Smoking in a Male Japanese Population. International Journal of Environmental Research and Public Health, 2010, 7, 2953-2964.	2.6	28
30	Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque. Biochemical Pharmacology, 2013, 85, 1837-1847.	4.4	28
31	Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regulatory Toxicology and Pharmacology, 2013, 65, 316-324.	2.7	28
32	Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor. Chemical Research in Toxicology, 2014, 27, 304-308.	3. 3	28
33	Rat Cytochrome P450 2C11 in Liver Microsomes Involved in Oxidation of Anesthetic Agent Propofol and Deactivated by Prior Treatment with Propofol. Drug Metabolism and Disposition, 2006, 34, 1803-1805.	3.3	27
34	Inter-individual Variation in Flavin-containing Monooxygenase 3 in Livers from Japanese: Correlation with Hepatic Transcription Factors. Drug Metabolism and Pharmacokinetics, 2009, 24, 218-225.	2.2	27
35	Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450. Drug Metabolism and Disposition, 2014, 42, 867-871.	3.3	27
36	Physiologically Based Pharmacokinetic Models Predicting Renal and Hepatic Concentrations of Industrial Chemicals after Virtual Oral Doses in Rats. Chemical Research in Toxicology, 2020, 33, 1736-1751.	3.3	27

#	Article	IF	Citations
37	Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan. Xenobiotica, 2015, 45, 766-772.	1.1	26
38	Human biofluid concentrations of mono(2-ethylhexyl)phthalate extrapolated from pharmacokinetics in chimeric mice with humanized liver administered with di(2-ethylhexyl)phthalate and physiologically based pharmacokinetic modeling. Environmental Toxicology and Pharmacology, 2015, 39, 1067-1073.	4.0	25
39	Human Blood Concentrations of Dichlorodiphenyltrichloroethane (DDT) Extrapolated from Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling. Journal of Health Science, 2010, 56, 566-575.	0.9	24
40	Developmental variations in metabolic capacity of flavinâ€containing monoâ€oxygenase 3 in childhood. British Journal of Clinical Pharmacology, 2011, 71, 585-591.	2.4	24
41	Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (<i>Callithrix jacchus</i>). Xenobiotica, 2016, 46, 163-168.	1.1	24
42	Activation and Deactivation of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine by Cytochrome P450 Enzymes and Flavin-Containing Monooxygenases in Common Marmosets (<i>Callithrix jacchus</i>). Drug Metabolism and Disposition, 2015, 43, 735-742.	3.3	23
43	<i>In Silico</i> Prediction of Input Parameters for Simplified Physiologically Based Pharmacokinetic Models for Estimating Plasma, Liver, and Kidney Exposures in Rats after Oral Doses of 246 Disparate Chemicals. Chemical Research in Toxicology, 2021, 34, 507-513.	3.3	23
44	Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Molecular Genetics and Metabolism, 2012, 107, 330-334.	1.1	22
45	Pharmacokinetics and effects on serum cholinesterase activities of organophosphorus pesticides acephate and chlorpyrifos in chimeric mice transplanted with human hepatocytes. Regulatory Toxicology and Pharmacology, 2014, 70, 468-473.	2.7	22
46	Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. Biochemical Pharmacology, 2015, 95, 110-114.	4.4	22
47	Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling. Regulatory Toxicology and Pharmacology, 2015, 72, 71-76.	2.7	22
48	Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. Biochemical Pharmacology, 2012, 84, 1691-1695.	4.4	21
49	Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers. Drug Metabolism and Disposition, 2016, 44, 911-915.	3. 3	21
50	Human plasma concentrations of herbicidal carbamate molinate extrapolated from the pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regulatory Toxicology and Pharmacology, 2014, 70, 214-221.	2.7	20
51	Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodiumâ€dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. Biopharmaceutics and Drug Disposition, 2016, 37, 491-506.	1.9	20
52	Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. Xenobiotica, 2017, 47, 844-848.	1,1	20
53	Possibility of Influence of Midazolam Sedation on the Diagnosis of Brain Death: Concentrations of Active Metabolites after Cessation of Midazolam. Yakugaku Zasshi, 2003, 123, 811-815.	0.2	19
54	Glucuronidation of Propofol and Its Analogs by Human and Rat Liver Microsomes Biological and Pharmaceutical Bulletin, 2003, 26, 216-219.	1.4	19

#	Article	IF	CITATIONS
55	Evaluation of 89 Compounds for Identification of Substrates for Cynomolgus Monkey CYP2C76, a New Bupropion/Nifedipine Oxidase. Drug Metabolism and Disposition, 2015, 43, 27-33.	3.3	19
56	Three Novel Single Nucleotide Polymorphisms of the FMO3 Gene in a Japanese Population. Drug Metabolism and Pharmacokinetics, 2006, 21, 245-247.	2.2	18
57	Relationships between flavinâ€containing monoâ€oxygenase 3 (<i><scp>FMO3</scp></i>) genotype and trimethylaminuria phenotype in a <scp>J</scp> apanese population. British Journal of Clinical Pharmacology, 2014, 77, 839-851.	2.4	18
58	Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica, 2015, 45, 881-886.	1.1	18
59	Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. Drug Metabolism and Pharmacokinetics, 2015, 30, 70-74.	2.2	18
60	Steady-State Human Pharmacokinetics of Monobutyl Phthalate Predicted by Physiologically Based Pharmacokinetic Modeling Using Single-Dose Data from Humanized-Liver Mice Orally Administered with Dibutyl Phthalate. Chemical Research in Toxicology, 2019, 32, 333-340.	3.3	18
61	Molecular and functional characterization of flavin-containing monooxygenases in pigs, dogs, and cats. Biochemical Pharmacology, 2022, 202, 115125.	4.4	18
62	In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. Biochemical Pharmacology, 2018, 152, 272-278.	4.4	16
63	Altered bupivacaine pharmacokinetics by MgSO4 in rats. Canadian Journal of Anaesthesia, 2004, 51, 93-94.	1.6	15
64	Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human <i>P450 3A</i> -Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry. Chemical Research in Toxicology, 2016, 29, 1279-1281.	3.3	15
65	Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1083-1090.	2.5	15
66	Missense and Nonsense Mutations of the Flavin-containing Monooxygenase 3 Gene in a Japanese Cohort. Drug Metabolism and Pharmacokinetics, 2007, 22, 61-64.	2.2	14
67	Complex Mechanism Underlying Transcriptional Control of the Haplotyped Flavin-containing Monooxygenase 3 (FMO3) Gene in Japanese: Different Regulation between Mutations in 5′-Upstream Distal Region and Common Element in Proximal Region. Drug Metabolism and Pharmacokinetics, 2008, 23, 54-58.	2.2	14
68	Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica, 2013, 43, 1037-1042.	1.1	14
69	Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. Xenobiotica, 2014, 44, 10-16.	1.1	14
70	Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database. Drug Metabolism and Pharmacokinetics, 2019, 34, 334-339.	2.2	13
71	Pharmacokinetic Investigation of Increased Efficacy Against Malignant Gliomas of Carboplatin Combined With Hyperbaric Oxygenation. Neurologia Medico-Chirurgica, 2009, 49, 193-197.	2.2	12
72	Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase. Drug Metabolism and Disposition, 2015, 43, 1119-1122.	3.3	12

#	Article	IF	CITATIONS
73	Machine Learning Prediction of the Three Main Input Parameters of a Simplified Physiologically Based Pharmacokinetic Model Subsequently Used to Generate Time-Dependent Plasma Concentration Data in Humans after Oral Doses of 212 Disparate Chemicals. Biological and Pharmaceutical Bulletin, 2021, , .	1.4	12
74	Pharmacokinetics of Fluconazole and Fosfluconazole after Intraperitoneal Administration to Peritoneal Dialysis Rats. Drug Metabolism and Pharmacokinetics, 2005, 20, 485-490.	2.2	11
75	Effects of Propofol Analogs on Glucuronidation of Propofol, an Anesthetic Drug, by Human Liver Microsomes. Drug Metabolism Letters, 2007, 1, 77-79.	0.8	11
76	Bonitos with Low Content of Malodorous Trimethylamine as Palliative Care for Self-reported Japanese Trimethylaminuria Subjects. Drug Metabolism and Pharmacokinetics, 2009, 24, 549-552.	2.2	11
77	A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles. Clinica Chimica Acta, 2012, 413, 1675-1677.	1.1	11
78	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for <i>cytochrome P450 2C19</i> <ir> <ir> <ir> <ir> <ir> <ir> <ir> </ir> 720-726.</ir></ir></ir></ir></ir></ir>	1.1	11
79	Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA. Journal of Toxicological Sciences, 2018, 43, 369-375.	1.5	11
80	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharmaceutics and Drug Disposition, 2019, 40, 350-357.	1.9	11
81	Novel variants and haplotypes of human <i>flavin-containing monooxygenase 3</i> gene associated with Japanese subjects suffering from trimethylaminuria. Xenobiotica, 2019, 49, 1244-1250.	1.1	11
82	Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method. Clinica Chimica Acta, 2011, 412, 1249-1251.	1.1	10
83	Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria. Molecular Genetics and Metabolism Reports, 2015, 5, 89-93.	1.1	10
84	Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes. Clinica Chimica Acta, 2015, 441, 71-74.	1.1	10
85	Human plasma and liver concentrations of styrene estimated by combining a simple physiologically based pharmacokinetic model with rodent data. Journal of Toxicological Sciences, 2019, 44, 543-548.	1.5	10
86	Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources. Drug Metabolism and Pharmacokinetics, 2021, 38, 100387.	2.2	10
87	Human Liver Enzymes Responsible for Metabolic Elimination of Tyramine, a Vasopressor Agent from Daily Food. Drug Metabolism Letters, 2011, 5, 216-219.	0.8	9
88	Human pharmacokinetic profiling of the dipeptidyl peptidaseâ€N inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Biopharmaceutics and Drug Disposition, 2015, 36, 148-162.	1.9	9
89	Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects. International Journal of Food Sciences and Nutrition, 2017, 68, 1013-1020.	2.8	9
90	Human plasma metabolic profiles of benzydamine, a flavin-containing monooxygenase probe substrate, simulated with pharmacokinetic data from control and humanized-liver mice. Xenobiotica, 2018, 48, 117-123.	1.1	9

#	Article	IF	CITATIONS
91	Dihydrocodeine Overdoses in a Neonate and in a 14-year-old Girl Who Were Both Genotyped as Cytochrome P450 2D6*1/*10-*36: Comparing Developmental Ages and Drug Monitoring Data With the Results of Pharmacokinetic Modeling. Therapeutic Drug Monitoring, 2018, 40, 162-165.	2.0	9
92	Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6. Drug Metabolism and Pharmacokinetics, 2020, 35, 191-200.	2.2	9
93	Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 6.	1.0	9
94	An Updated <i>In Silico</i> Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats. Chemical Research in Toxicology, 2021, 34, 2180-2183.	3.3	9
95	Metabolic profiles of coumarin in human plasma extrapolated from a rat data set with a simplified physiologically based pharmacokinetic model. Journal of Toxicological Sciences, 2020, 45, 695-700.	1.5	9
96	Marmoset Flavin-Containing Monooxygenase 3 in the Liver Is a Major Benzydamine and Sulindac Sulfide Oxygenase. Drug Metabolism and Disposition, 2017, 45, 497-500.	3.3	8
97	Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R-omeprazole and S-warfarin using individual marmoset physiologically based pharmacokinetic models. Xenobiotica, 2018, 48, 1072-1077.	1.1	8
98	<i>R</i> -warfarin clearances from plasma associated with polymorphic <i>cytochrome P450 2C19</i> and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys. Xenobiotica, 2018, 48, 206-210.	1.1	8
99	Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4′- and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice. Chemical Research in Toxicology, 2020, 33, 634-639.	3.3	8
100	Metabolic Profiles of Tetrabromobisphenol A in Humans Extrapolated from Humanized-Liver Mouse Data Using a Simplified Physiologically Based Pharmacokinetic Model. Chemical Research in Toxicology, 2021, 34, 522-528.	3.3	8
101	Metabolic profiles for the pyrrolizidine alkaloid neopetasitenine and its metabolite petasitenine in humans extrapolated from rat <i>in vivo</i> and <i>in vitro</i> data sets using a simplified physiologically based pharmacokinetic model. Journal of Toxicological Sciences, 2021, 46, 391-399.	1.5	8
102	Trimethylamine generation in patients receiving hemodialysis treated with L-carnitine. CKJ: Clinical Kidney Journal, 2014, 7, 329-329.	2.9	7
103	Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances. Biopharmaceutics and Drug Disposition, 2015, 36, 636-643.	1.9	7
104	Analysis of gene expression for microminipig liver transcriptomes using parallel longâ€read technology and shortâ€read sequencing. Biopharmaceutics and Drug Disposition, 2016, 37, 220-232.	1.9	7
105	Human urinary concentrations of monoisononyl phthalate estimated using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally administered with diisononyl phthalate. Xenobiotica, 2019, 49, 513-520.	1.1	7
106	Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital. Journal of Pharmaceutical Health Care and Sciences, 2020, 6, 20.	1.0	7
107	Different Hepatic Concentrations of Bromobenzene, 1,2-Dibromobenzene, and 1,4-Dibromobenzene in Humanized-Liver Mice Predicted Using Simplified Physiologically Based Pharmacokinetic Models as Putative Markers of Toxicological Potential. Chemical Research in Toxicology, 2020, 33, 3048-3053.	3.3	7
108	Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. Drug Metabolism and Pharmacokinetics, 2020, 35, 354-360.	2.2	7

#	Article	IF	CITATIONS
109	Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes. Journal of Toxicological Sciences, 2021, 46, 311-317.	1.5	7
110	A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects. Drug Metabolism and Pharmacokinetics, 2021, 41, 100420.	2.2	7
111	Human Plasma Concentrations of Tolbutamide and Acetaminophen Extrapolated from <i>in vivo</i> Animal Pharmacokinetics Using <i>in vitro</i> Human Hepatic Clearances and Simple Physiologically Based Pharmacokinetic Modeling for Radio-labeled Microdose Clinical Studies. Radioisotopes, 2015, 64, 509-519.	0.2	7
112	Dataset for genotyping validation of cytochrome P450 2A6 whole-gene deletion (CYP2A6 * 4) by real-time polymerase chain reaction platforms. Data in Brief, 2015, 5, 642-645.	1.0	6
113	Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques. Drug Metabolism and Pharmacokinetics, 2019, 34, 104-107.	2.2	6
114	Expression of functional sulfotransferases (SULT) 1A1, 1A3, 1B1, 1C2, 1E1, and 2A1 in common marmosets. Biochemical Pharmacology, 2020, 180, 114189.	4.4	6
115	Different Effects of <i>TERT</i> , <i>TP</i> 63, and <i>CYP</i> 2 <i>A</i> 6 Polymorphism on Individual Risk of Tobacco-Related Lung Cancer in Male Japanese Smokers. Journal of Cancer Therapy, 2011, 02, 690-696.	0.4	6
116	Roles of human cytochrome P450 1A2 in coumarin 3,4-epoxidation mediated by untreated hepatocytes and by those metabolically inactivated with furafylline in previously transplanted chimeric mice. Journal of Toxicological Sciences, 2021, 46, 525-530.	1.5	6
117	Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes. Drug Metabolism and Disposition, 2023, 51, 123-129.	3.3	6
118	Population Pharmacokinetic-Pharmacodynamic Modeling of TF-505 Using Extension of Indirect Response Model by Incorporating a Circadian Rhythm in Healthy Volunteers. Biological and Pharmaceutical Bulletin, 2005, 28, 1455-1461.	1.4	5
119	High-performance Liquid Chromatographic Assay for Carboplatin in Ultrafiltered Plasma Combined with Hyperbaric Oxygenation. Drug Metabolism and Pharmacokinetics, 2006, 21, 429-431.	2.2	5
120	Efavirenz clearances <i>in vitro</i> and <i>in vivo</i> in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. Biopharmaceutics and Drug Disposition, 2017, 38, 439-442.	1.9	5
121	Human plasma and urinary metabolic profiles of trimethylamine and trimethylamine <i>N</i> -oxide extrapolated using a simple physiologically based pharmacokinetic model. Journal of Toxicological Sciences, 2017, 42, 485-490.	1.5	5
122	Human plasma concentrations of trimethylamine <i>N</i> -oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice. Journal of Toxicological Sciences, 2018, 43, 387-393.	1.5	5
123	Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital. Xenobiotica, 2019, 49, 1001-1006.	1.1	5
124	Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. Xenobiotica, 2020, 50, 1023-1031.	1.1	5
125	Predicted Contributions of Flavin-containing Monooxygenases to the N-oxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants. Current Drug Metabolism, 2021, 22, 208-214.	1.2	5
126	Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam. Drug Metabolism and Pharmacokinetics, 2021, 39, 100394.	2,2	5

#	Article	IF	CITATIONS
127	Pharmacokinetic modeling of over-the-counter drug diphenhydramine self-administered in overdoses in Japanese patients admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 32.	1.0	5
128	Pharmacokinetics of loxoprofen in a self-administered overdose in a Japanese patient admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 33.	1.0	5
129	Effects of ADH1C, ALDH2, and CYP2A6 Polymorphisms on Individual Risk of Tobacco-Related Lung Cancer in Male Japanese Smokers. Journal of Cancer Therapy, 2013, 04, 29-35.	0.4	5
130	Correlation between the Physicochemical Property of Some Nonsteroidal Anti-inflammatory Drugs and Changes in Adenosine Triphosphate, Glutathione and Hemoglobin in Rat Erythrocytes. Biological and Pharmaceutical Bulletin, 2003, 26, 1155-1165.	1.4	4
131	Activities of Rat Cytochrome P450 3A and 2C Isoforms are Increased In Vivo by Magnesium Sulfate as Evidenced by Enhanced Oxidation of Bupivacaine and Testosterone in Liver Microsomes. Drug Metabolism and Pharmacokinetics, 2006, 21, 201-207.	2.2	4
132	Plasma and hepatic concentrations of acetaminophen and its primary conjugates after oral administrations determined in experimental animals and humans and extrapolated by pharmacokinetic modeling. Xenobiotica, 2021, 51, 316-323.	1.1	4
133	InÂvivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice. Drug Metabolism and Pharmacokinetics, 2021, 37, 100369.	2.2	4
134	Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers. Drug Metabolism Letters, 2017, 10, 240-243.	0.8	4
135	Pharmacokinetics of caffeine self-administered in overdose in a Japanese patient admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 36.	1.0	4
136	Further survey of genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found in an updated database of genome resources and identified by phenotyping for trimethylaminuria. Drug Metabolism and Pharmacokinetics, 2022, 46, 100465.	2.2	4
137	4'-Hydroxylation of Flurbiprofen by Rat Liver Microsomes in Fasting and Feeding Conditions. Biological and Pharmaceutical Bulletin, 2003, 26, 1448-1454.	1.4	3
138	Expression and metabolic activity of flavinâ€containing monooxygenase 1 in cynomolgus macaque kidney. Journal of Medical Primatology, 2019, 48, 51-53.	0.6	3
139	Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3). Drug Metabolism and Pharmacokinetics, 2020, 35, 571-573.	2.2	3
140	Differences in pharmacokinetics and haematotoxicities of aniline and its dimethyl derivatives orally administered in rats. Biological and Pharmaceutical Bulletin, 2021, 44, 1775-1780.	1.4	3
141	Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: insights into future personalized treatments. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 26.	1.0	3
142	Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes. Drug Metabolism and Pharmacokinetics, 2021, 40, 100412.	2.2	3
143	Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5′-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species. Journal of Toxicological Sciences, 2021, 46, 553-560.	1.5	3
144	Probe drug T-1032ÂN-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes inÂvitro and in humanized-liver mice inÂvivo. Drug Metabolism and Pharmacokinetics, 2022, 44, 100453.	2.2	3

#	Article	IF	Citations
145	Possible Origin of Rat Testicular Atrophy Induced by Di-n-Butyl Phthalate: Changes in the Activities of Some Enzymes during Rat Testis Perfusion under a Hypoxic Condition and with Mono-n-Butyl Phthalate Journal of Health Science, 2002, 48, 503-513.	0.9	2
146	Testicular Toxicity of Mono-n-Butyl Phthalate and Related Phthalates on Bound Iron in Rat Red Blood Cells Journal of Health Science, 2002, 48, 527-533.	0.9	2
147	Effects of Aspirin and/or Salicylate on Hydrolysis and Glucuronidation of Indomethacin in Rat Erythrocytes and Hepatocytes. Biological and Pharmaceutical Bulletin, 2003, 26, 675-682.	1.4	2
148	Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. Journal of Toxicological Sciences, 2012, 37, 639-643.	1.5	2
149	Novel variants in outer protein surface of flavin-containing monooxygenase 3 found in an Argentinian case with impaired capacity for trimethylamine N-oxygenation. Drug Metabolism and Pharmacokinetics, 2020, 35, 383-388.	2.2	2
150	Hepatotoxicological potential of P-toluic acid in humanised-liver mice investigated using simplified physiologically based pharmacokinetic models. Xenobiotica, 2021, 51, 1-7.	1.1	2
151	Different Effects of Polymorphic Flavin-Containing Monooxygenase 3 and Cytochrome P450 2A6 Activities on an Index of Arteriosclerosis as a Lifestyle-Related Disease in a General Population in Japan. Current Drug Metabolism, 2020, 21, 1161-1164.	1.2	2
152	Effects of Meat Intake Frequency and Polymorphic Cytochrome P450 2A6 Activity on Individual Colorectal Tumour Risk in a Japanese Cohort. Journal of Cancer Therapy, 2017, 08, 645-652.	0.4	2
153	Trivariate Linear Regression and Machine Learning Prediction of Possible Roles of Efflux Transporters in Estimated Intestinal Permeability Values of 301 Disparate Chemicals. Biological and Pharmaceutical Bulletin, 2022, , .	1.4	2
154	A Computer Program for Pharmacokinetics Based on Maximum Likelihood Estimation Using the Gamma Distribution with a Probability Density Function: Comparison with the Normal Distribution Biological and Pharmaceutical Bulletin, 2000, 23, 235-239.	1.4	1
155	Cytochrome P450 2A6 Phenotyping Based on Dietary Caffeine Intake in a Japanese Population of Non-smokers. Drug Metabolism Letters, 2012, 6, 67-72.	0.8	1
156	Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors. Biopharmaceutics and Drug Disposition, 2016, 37, 310-313.	1.9	1
157	Cytochrome P450 2A6 Phenotyping Based on Dietary Caffeine Intake in a Japanese Population of Non-smokers. Drug Metabolism Letters, 2012, 6, 67-72.	0.8	1
158	Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations. Xenobiotica, 2020, 50, 1413-1422.	1.1	0
159	Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1. Drug Metabolism and Pharmacokinetics, 2021, 39, 100398.	2.2	0
160	Genetic Polymorphism of Human Tissue Phenol Sulfotransferases Drug Metabolism and Pharmacokinetics, 2000, 15, 171-176.	0.0	0
161	Practical Application of Pharmacokinetic-Pharmacodynamic Modeling Drug Metabolism and Pharmacokinetics, 2000, 15, 452-460.	0.0	0